Navigation Links
PrimeraDx Appoints David Jackson as VP of Business Development
Date:1/3/2012

MANSFIELD, Mass., Jan. 3, 2012 /PRNewswire/ -- PrimeraDx today announced that David Jackson has been appointed as the Vice President of Business Development.

"David has extensive capabilities in companion diagnostic partnerships, and his experience with DxS and Qiagen is well aligned with the company's strategy to be the platform of choice in the burgeoning companion diagnostics market," said Matt McManus, President and CEO, PrimeraDx.

"PrimeraDx has the most innovative qPCR based MDx platform in this space," commented Dr. Jackson.  "The strong growth in complex, molecular-based companion diagnostic assays makes this an exciting time to develop strategic alliances based around the high multiplex and multi-modal capabilities of the ICEPlex platform."

David Jackson has over 13 years' experience in the healthcare technology and investment industries.  Most recently David was employed at Qiagen as a member of the Companion Diagnostics Partnerships team in Global Business Development. Prior to Qiagen he held a similar VP role with DxS, which was acquired by Qiagen in 2009.  He has held leadership positions in business and corporate development; strategic marketing; commercialization; and intellectual property analysis. Dr. Jackson earned a doctorate in the medical sciences from the Boston University School of Medicine; is trained and experienced as a US Patent Agent and Securities Analyst.

About PrimeraDx

PrimeraDx is a molecular diagnostics company that has developed, and is commercializing, a novel, game-changing clinical platform which combines PCR with capillary electrophoresis.  The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative, answers to the clinic.  The company is pursuing a two-pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion and enabling diagnostic products.  Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes.  PrimeraDx's technology represents the next generation of quantitative PCR.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeraDx Appoints Leroy Hood to its Scientific Advisory Board
2. PrimeraDx Appoints David Heffelfinger as VP of Engineering and Systems Development
3. PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA
4. China Health Resource Appoints USA Acquisition Counsel
5. Winner Medical Appoints BDO China as Independent Auditor
6. Marken Appoints New Head of Global Quality Assurance
7. Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board
8. Qforma Appoints Ian McGuinness as Vice President, Business Development
9. ZONARE Medical Systems Appoints Timothy S. Heher as Vice President of Finance
10. NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors
11. HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
Breaking Medicine News(10 mins):